⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
KVUE — Kenvue Inc.
Last scan (Sept. 15, 2026): price $17.91, RSI 35.56, relative volume 1.52x, MACD ⚪ No, score 44.65.
It's in a bullish underlying trend (above its 200-day average), and an RSI of 35.56 suggests it isn't overbought yet — there's room before the momentum runs out. Neither the MACD nor a range breakout gives a technical entry signal right now. Relative volume of 1.52x is somewhat above normal. The analysts' average target price implies a modest +8.9% upside.
Price chart
KVUE
Price: $17.81 · RSI (14): 45.21 · Rel. volume: 1.57x · Breakout: No
- Current price: ($17.81) — solid white line — the latest available closing price.
- Target price: ($19.5) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($17.6) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
KVUE
Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and…
- Buy 2
- Hold 12
- Sell 0
Average target price: $19.5 (+9.5% vs. current price) · range $18.0 – $23.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
In a reasonable range compared to the market's historical average (~20).
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Between 1 and 2: the price is roughly aligned with expected growth.
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Moderate leverage, normal in many industries.
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Healthy margin for most industries.
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Pays out a portion of its earnings as cash to shareholders on a recurring basis.
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Less volatile than the overall market (S&P 500 = 1.0).
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.